Apple Crushes It and It's All About Services, Plus Final Hints on Tesla

Stocks Continue To Rise With More Gains To Come

Subscribe to receive this FREE daily commentary directly in your email

[widget id=”text-22″]

[widget id=”text-19″]

[widget id=”text-28″]

Stocks Continue To Rise With More Gains To Come

[widget id=”text-19″]
MICHAEL KRAMER AND THE CLIENTS OF MOTT CAPITAL OWN SHARES OF AAPL & CELG

S&P 500

Stocks continued their advance on Friday, with the S&P 500 ($SPY) rising by roughly 40 basis points on the day. The S&P 500 is now trading around 2,840 rebounding nicely from the sell-off of last week.  As the hourly chart shows, the S&P 500 has now successfully tested and retested technical support around 2,794 to 2,800 on a few occasions, and that support has held every time. It furthers my confidence that equity prices will continue their advance over August.

spx by Scorpio244 on TradingView.com

[widget id=”text-28″]

Technology Stocks

Technology stocks ($XLK) have also managed to find a bounce of late. Bouncing off an uptrend starting in early February. xlk by Scorpio244 on TradingView.com

Apple

Apple ($AAPL) has been a big reason for the markets rebound this week, and for now, Apple appears to have firmly broken out and should have a stable layer of technical support around $200. In my subscriber section today, I went through the reason’s I think Apple’s stock may rise by about 50 percent over the next year or so.  Why Apple May Rise By 50% aapl by Scorpio244 on TradingView.com

Facebook

Facebook ($FB), on the other hand, is in a different boat, and for now, the $166 level continues to hold firmly. The upside for now looks limited around $183. fb by Scorpio244 on TradingView.com

Amazon

To this point, Amazon ($AMZN) has been unable to get back above resistance at $1840. The recent price action in the stock reminds me of what happened after the first quarter results. The stock may be stuck in the mud for a while longer. amzn by Scorpio244 on TradingView.com

Biotech

The smaller biotech ($XBI) stocks have struggled lately, with the XBI failing to break out at $101 despite multiple attempts. For now, an uptrend holds in place. xbi by Scorpio244 on TradingView.com The large-cap weighted ($IBB)  has been a different story, trending higher. That is likely because biotech heavyweights such as Celgene and Regeneron have started rising once again.

Celgene

Celgene’s stocks ($CELG) look as though it can continue to rise to around $97. celg by Scorpio244 on TradingView.com

Regeneron

While Regeneron  ($REGN) just broke over a key resistance at around $393. regn by Scorpio244 on TradingView.com That is going to be it for today! -Mike

Visit a Sponsor:

[widget id=”text-22″]

[widget id=”text-23″]

PHOTO CREDIT VIA FLICKR Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.  #apple #amazon #biotech #technology #stocks #sp500 #celgene #regeneron #facebook

Add your email to The Market Chronicles' growing list of daily readers. A FREE market commentary on the trading day's most critical and least apparent events!

Add your email to The Market Chronicles' growing list of daily readers. A FREE market commentary on the trading day's most critical and least apparent events!

Unlock Deeper Insights with Exclusive Member-Only Video Content on The Market Chronicles YouTube Channel – Just $34.99/Month

[youtube-feed feed=7]

Subscribe to receive this FREE daily commentary directly in your email

This report contains independent commentary to be used for informational and educational purposes only. Michael Kramer is a member and investment adviser representative with Mott Capital Management. Mr. Kramer is not affiliated with this company and does not serve on the board of any related company that issued this stock. All opinions and analyses presented by Michael Kramer in this analysis or market report are solely Michael Kramer’s views. Readers should not treat any opinion, viewpoint, or prediction expressed by Michael Kramer as a specific solicitation or recommendation to buy or sell a particular security or follow a particular strategy. Michael Kramer’s analyses are based upon information and independent research that he considers reliable, but neither Michael Kramer nor Mott Capital Management guarantees its completeness or accuracy, and it should not be relied upon as such. Michael Kramer is not under any obligation to update or correct any information presented in his analyses. Mr. Kramer’s statements, guidance, and opinions are subject to change without notice. Past performance is not indicative of future results. Neither Michael Kramer nor Mott Capital Management guarantees any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment commentary presented in this analysis. Strategies or investments discussed may fluctuate in price or value. Investments or strategies mentioned in this analysis may not be suitable for you. This material does not consider your particular investment objectives, financial situation, or needs and is not intended as a recommendation appropriate for you. You must make an independent decision regarding investments or strategies in this analysis. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Before acting on information in this analysis, you should consider whether it is suitable for your circumstances and strongly consider seeking advice from your own financial or investment adviser to determine the suitability of any investment.